Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients

Treatment of metastatic kidney cancer has changed dramatically in the past years with the use of VEGF-targeted therapies and mTOR inhibitors. However, resistance occurs. We report here two cases of patients who benefited, both on disease control and side effects, from the addition of bevacizumab to...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyle, H., Négrier, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2011
Materias:
Published: November, 2011
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237108/
https://www.ncbi.nlm.nih.gov/pubmed/22171218
http://dx.doi.org/10.1159/000334581
_version_ 1782218841169854464
author Boyle, H.
Négrier, S.
author_facet Boyle, H.
Négrier, S.
author_sort Boyle, H.
collection PubMed
description Treatment of metastatic kidney cancer has changed dramatically in the past years with the use of VEGF-targeted therapies and mTOR inhibitors. However, resistance occurs. We report here two cases of patients who benefited, both on disease control and side effects, from the addition of bevacizumab to temsirolimus, after progression on the mTOR inhibitor alone.
format Online
Article
Text
id pubmed-3237108
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-32371082011-12-14 Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients Boyle, H. Négrier, S. Case Rep Oncol Published: November, 2011 Treatment of metastatic kidney cancer has changed dramatically in the past years with the use of VEGF-targeted therapies and mTOR inhibitors. However, resistance occurs. We report here two cases of patients who benefited, both on disease control and side effects, from the addition of bevacizumab to temsirolimus, after progression on the mTOR inhibitor alone. S. Karger AG 2011-11-11 /pmc/articles/PMC3237108/ /pubmed/22171218 http://dx.doi.org/10.1159/000334581 Text en Copyright © 2011 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published: November, 2011
Boyle, H.
Négrier, S.
Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
title Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
title_full Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
title_fullStr Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
title_full_unstemmed Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
title_short Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
title_sort addition of bevacizumab to temsirolimus in kidney cancer patients
topic Published: November, 2011
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237108/
https://www.ncbi.nlm.nih.gov/pubmed/22171218
http://dx.doi.org/10.1159/000334581
work_keys_str_mv AT boyleh additionofbevacizumabtotemsirolimusinkidneycancerpatients
AT negriers additionofbevacizumabtotemsirolimusinkidneycancerpatients

Ejemplares similares